Drug pharmacokinetics in the obese population: challenging common assumptions on predictors of obesity-related parameter changes
T Zhang, EHJ Krekels, C Smit… - Expert opinion on drug …, 2022 - Taylor & Francis
Introduction Obesity is associated with many physiological changes. We review available
evidence regarding five commonly accepted assumptions to a priori predict the impact of …
evidence regarding five commonly accepted assumptions to a priori predict the impact of …
Update on antithrombotic therapy and body mass: a clinical consensus statement of the European Society of Cardiology Working Group on Cardiovascular …
Obesity and underweight are a growing health problem worldwide and a challenge for
clinicians concerning antithrombotic therapy, due to the associated risks of thrombosis …
clinicians concerning antithrombotic therapy, due to the associated risks of thrombosis …
Drug disposition protein quantification in matched human jejunum and liver from donors with obesity
Mathematical models, such as physiologically‐based pharmacokinetic models, are used to
predict, for example, drug disposition and toxicity. However, populations differ in the …
predict, for example, drug disposition and toxicity. However, populations differ in the …
Selective COX-2 inhibitors after bariatric surgery: Celecoxib, etoricoxib and etodolac post-bariatric solubility/dissolution and pharmacokinetics
D Porat, O Dukhno, M Partook-Maccabi… - International Journal of …, 2023 - Elsevier
Anatomical/physiological gastrointestinal changes after bariatric surgery may influence the
fate of orally administered drugs. Since non-selective NSAIDs are not well-tolerated post …
fate of orally administered drugs. Since non-selective NSAIDs are not well-tolerated post …
Short‐and long‐term effects of body weight, calorie restriction and gastric bypass on CYP1A2, CYP2C19 and CYP2C9 activity
Aim Roux‐en‐Y gastric bypass (RYGB) may influence drug disposition due to surgery‐
induced gastrointestinal alterations and/or subsequent weight loss. The objective was to …
induced gastrointestinal alterations and/or subsequent weight loss. The objective was to …
Effects of sleeve gastrectomy and Roux-en-Y gastric bypass on escitalopram pharmacokinetics: a cohort study
G Schoretsanitis, M Strømmen… - Therapeutic Drug …, 2023 - journals.lww.com
Background: Changes in the gastrointestinal physiology after bariatric surgery may affect the
pharmacokinetics of medications. Data on the impact of different surgical techniques on the …
pharmacokinetics of medications. Data on the impact of different surgical techniques on the …
[PDF][PDF] Redefining statin dosage post-gastric bypass: insights from a population pharmacokinetics-pharmacodynamics link approach
ACC Costa, JIM Medeiros, W Kang, PA Yamamoto… - J. Clin …, 2024 - sacaccp.org
Roux-en-Y gastric bypass (RYGB) involves creating a small stomach pouch, bypassing part
of the small intestine, and rerouting the digestive tract. These alterations can potentially …
of the small intestine, and rerouting the digestive tract. These alterations can potentially …
Update on antithrombotic therapy and body mass. A clinical consensus Statement of the ESC Working Group on Cardiovascular Pharmacotherapy and the ESC …
Obesity and underweight are a growing health problem worldwide and a challenge for
clinicians concerning antithrombotic therapy, due to the associated risks of thrombosis …
clinicians concerning antithrombotic therapy, due to the associated risks of thrombosis …
Digoxin pharmacokinetics in patients with obesity before and after a gastric bypass or a strict diet compared with normal weight individuals
Abstract Background and Objective Several drugs on the market are substrates for P-
glycoprotein (P-gp), an efflux transporter highly expressed in barrier tissues such as the …
glycoprotein (P-gp), an efflux transporter highly expressed in barrier tissues such as the …